In 2018, guoyuankang launched a clinical trial of small molecule pectin as a intestinal probiotics in Europe jointly with American companies.

Experiments have proved that small molecular pectin has a good effect on promoting intestinal probiotics, especially for anti-three-high roche bacillus and anti-depression flavonifractor bacteria. At the same time, the experiment proved that the small molecule pectin has better probiotics effect than the ordinary pectin, the effective rate is twice as fast as the ordinary pectin.
For more details of the trial, see the new patents to be issued in the future.